Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Invasive Mold Infections: later-stage trial registry

1 of 1 indexed Invasive Mold Infections trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Invasive Mold Infections: 1 US clinical trial tracked, 1 recruiting.

Invasive Mold Infections is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Basilea Pharmaceutica, running 1 of these trials.

Enrollment posture brief

Registry condition invasive-mold-infections

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Invasive Mold Infections (this)Invasive Mold Infections (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Invasive Mold Infections

Invasive Mold Infections lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Invasive Mold Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Invasive Mold Infections is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Invasive Mold Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fosmanogepix oral tablet Drug
1 trials
Standard of care antifungal therapy Drug
1 trials
Fosmanogepix IV infusion Drug
1 trials

US sites by state

Facility locations filed on Invasive Mold Infections trials. A trial with sites in several states counts in each.

Texas 1 trials
North Carolina 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
Maryland 1 trials
Kentucky 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Invasive Mold Infections page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Invasive Mold Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Basilea Pharmaceutica sponsors the most Invasive Mold Infections trials on record, review their full trial history before evaluating a specific study. See Basilea Pharmaceutica's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Invasive Mold Infections condition card totals 1 registered trials; most-linked intervention Fosmanogepix oral tablet; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.